IRVINE, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, today announced that it has been selected by Pathology, Inc. to be its exclusive provider of chromosomal microarray tests for the Products of Conception (POC) testing market throughout the United States. POC testing, also referred to as miscarriage testing, is a subset of the overall prenatal testing market.
Pathology, Inc. And CombiMatrix Expand Partnership In Prenatal Testing Market
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts